Regeneron Pharmaceuticals, Inc.

Carrie Brownstein

Israel Lowy

Gavin Thurston

Bindu Varghese

Eric L Smith

Samuel H Davis

Jessica Kirshner

Eric B Smith

Lieve Lucille Adriaens

Jessica R Kirshner

Eric Smith

Samuel Davis

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.

Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies

The present invention relates to a method (dosage regimen) for administering a CD3&#xd7;CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3&#xd7;CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3&#xd7;CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose, the second dose, and any subsequent doses are also part of the present invention.

Methods for tumor treatment using CD3XCD20 bispecific antibody

Growing community of inventors

New York, NY, United States of America

Carrie Brownstein